smartbax, a Munich, Germany-based biotech company developing antibiotics against multi-drug resistant bacteria, raised €1.2M in Seed funding.
The round, which brought the total amount to €1.9M, saw participation from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds.
The company intends to use the funds to advance its small molecule antibiotics through preclinical studies, expand its scientific team to further develop its research platforms and identify novel solutions against multi-drug resistant pathogens.
Founded in 2021 by Dr. Robert Macsics, Marco Janezic, and Prof. Dr. Stephan Sieber and supported by BIVF with a first pre-seed financing of €700,000, smartbax is developing antibiotics to address the increasing spread of multidrug-resistant bacteria. Its product candidates act via a double-targeted mechanism of action. This not only inhibits essential processes in the energy metabolism of multi-resistant bacteria, but also creates a stimulation of the bacteria’s protein secretion, which leads to a self-digest of the cells.
The company’s scientific foundation is based on research derived by Prof. Dr. Sieber’s research group from the Technical University of Munich.
FinSMEs
23/05/2023